Diabetes Drug Class May Hold Promise for Gout Prevention
Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce the risk for gout among adults with type 2 diabetes, new research suggests. The study, involving more than 200,000 individuals from a US commercial insurance database, was published online January 13 in Annals of Internal Medicine by Michael Fralick, MD, PhD, and colleagues. The glycosuria produced by SGLT2 inhibitors results in secretion of uric acid into the urine and a reduction in serum uric acid levels, but a relationship with gout had not been previously shown.
@minti In this new study, there was a nearly 40% relative risk reduction in gout among adults prescribed SGLT2 inhibitors compared with those prescribed glucagon-like peptide-1 (GLP-1) receptor agonists, which do not decrease uric acid levels. The absolute risk reduction was about three fewer adults with gout per 1000 person-years.